AstraZeneca bolsters heart failure and metabolic disease research
This article was originally published in Scrip
AstraZeneca and its MedImmune unit have signed a couple of early stage research deals aimed at boosting their cardiovascular and metabolic pipeline efforts – one of its three core therapeutic areas.
You may also be interested in...
Positive Phase II data for Aptinyx’s novel NMDA receptor modulator are strong enough to take the product into a pivotal study in this difficult-to-treat area.
Orchard Therapeutics is on the cusp of the first approval for its ex vivo gene therapy, Libmeldy, for metachromatic leukodystrophy.
Gilead/Kite’s second CAR-T product is given the go-ahead for approval by the CHMP for mantle cell lymphoma.